{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:04:52Z","timestamp":1781780692584,"version":"3.54.5"},"reference-count":44,"publisher":"Elsevier BV","issue":"35","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.vaccine.2022.07.023","type":"journal-article","created":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T07:18:12Z","timestamp":1658906292000},"page":"5189-5196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2"],"prefix":"10.1016","volume":"40","author":[{"given":"Florencia","family":"Rammauro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Carri\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Olivero-Deibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00edn","family":"Fl\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Pritsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1244-7411","authenticated-orcid":false,"given":"Sergio","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7881","key":"10.1016\/j.vaccine.2022.07.023_b0005","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/d41586-021-02796-w","article-title":"China's COVID vaccines have been crucial - now immunity is waning","volume":"598","author":"Mallapaty","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2022.07.023_b0010","unstructured":"Ritchie H, Mathieu E, Rod\u00e9s-Guirao L, et al. Coronavirus pandemic (COVID-19). Our World in Data; 2020. <https:\/\/ourworldindata.org\/coronavirus>."},{"issue":"2","key":"10.1016\/j.vaccine.2022.07.023_b0015","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"27","key":"10.1016\/j.vaccine.2022.07.023_b0020","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.vaccine.2022.07.023_b0025","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2107715","article-title":"Effectiveness of an inactivated SARS-CoV-2 vaccine in chile","volume":"385","author":"Jara","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.07.023_b0030","article-title":"Effectiveness of SARS-CoV-2 mRNA vaccines for preventing covid-19 hospitalizations in the United States","author":"Tenforde","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2022.07.023_b0035","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41577-021-00578-z","article-title":"Immunological mechanisms of vaccine-induced protection against COVID-19 in humans","volume":"21","author":"Sadarangani","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.07.023_b0040","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S2666-5247(21)00267-6","article-title":"Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis","volume":"3","author":"Cromer","year":"2022","journal-title":"Lancet Microbe"},{"issue":"7","key":"10.1016\/j.vaccine.2022.07.023_b0045","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.chom.2021.06.001","article-title":"A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses","volume":"29","author":"Tauzin","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"24","key":"10.1016\/j.vaccine.2022.07.023_b0050","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months","volume":"385","author":"Levin","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.vaccine.2022.07.023_b0055","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3201\/eid2802.211834","article-title":"Effectiveness of mRNA BNT162b2 vaccine 6 months after vaccination among patients in large health maintenance organization, Israel","volume":"28","author":"Kertes","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2022.07.023_b0060","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijid.2021.09.078","article-title":"Antibody response to the inactivated SARS-CoV-2 vaccine among healthcare workers","volume":"113","author":"Cucunawangsih","year":"2021","journal-title":"Indonesia. Int J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2022.07.023_b0065","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41591-022-01705-6","article-title":"Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination","volume":"28","author":"P\u00e9rez-Then","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2022.07.023_b0070","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-022-01704-7","article-title":"Neutralizing antibodies against the SARS-CoV-2 Omicron variant following homologous and heterologous CoronaVac or BNT162b2 vaccination","author":"Cheng","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.vaccine.2022.07.023_b0075","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nri.2017.106","article-title":"Beyond binding: antibody effector functions in infectious diseases","volume":"18","author":"Lu","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2022.07.023_b0080","doi-asserted-by":"crossref","first-page":"100405","DOI":"10.1016\/j.xcrm.2021.100405","article-title":"Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination","volume":"2","author":"Gorman","year":"2021","journal-title":"Cell Rep Med"},{"issue":"19","key":"10.1016\/j.vaccine.2022.07.023_b0085","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months","volume":"385","author":"Thomas","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2022.07.023_b0090","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.vaccine.2021.11.051","article-title":"Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection","volume":"40","author":"Dinc","year":"2022","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2022.07.023_b0095","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1016\/S2666-5247(21)00177-4","article-title":"Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19","volume":"2","author":"Lim","year":"2021","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.vaccine.2022.07.023_b0100","article-title":"Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong","author":"Mok","year":"2021","journal-title":"Respirology"},{"issue":"3","key":"10.1016\/j.vaccine.2022.07.023_b0105","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/ckj\/sfab291","article-title":"Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant","volume":"15","author":"Seija","year":"2022","journal-title":"Clin Kidney J"},{"issue":"5","key":"10.1016\/j.vaccine.2022.07.023_b0110","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/lt.26400","article-title":"Low Immunoglobulin G antibody levels against severe acute respiratory disease coronavirus 2 after 2-dose vaccination among liver transplantation recipients","volume":"28","author":"Prieto","year":"2022","journal-title":"Liver Transpl"},{"issue":"10308","key":"10.1016\/j.vaccine.2022.07.023_b0115","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(21)02046-8","article-title":"Considerations in boosting COVID-19 vaccine immune responses","volume":"398","author":"Krause","year":"2021","journal-title":"Lancet"},{"issue":"7871","key":"10.1016\/j.vaccine.2022.07.023_b0120","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/d41586-021-02158-6","article-title":"COVID vaccine boosters: the most important questions","volume":"596","author":"Callaway","year":"2021","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.vaccine.2022.07.023_b0125","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/s41591-021-01464-w","article-title":"Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19\/mRNA vaccination","volume":"27","author":"Schmidt","year":"2021","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.vaccine.2022.07.023_b0130","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1056\/NEJMc2110716","article-title":"Heterologous ChAdOx1 nCoV-19 and mRNA-1273 vaccination","volume":"385","author":"Normark","year":"2021","journal-title":"N Engl J Med"},{"issue":"10319","key":"10.1016\/j.vaccine.2022.07.023_b0135","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0140-6736(21)02718-5","article-title":"Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial","volume":"399","author":"Stuart","year":"2022","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2022.07.023_b0140","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.vaccine.2021.11.083","article-title":"Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults","volume":"40","author":"Yorsaeng","year":"2022","journal-title":"Vaccine"},{"issue":"10324","key":"10.1016\/j.vaccine.2022.07.023_b0145","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(22)00094-0","article-title":"Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study","volume":"399","author":"Costa Clemens","year":"2022","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.vaccine.2022.07.023_b0150","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMc2115596","article-title":"Differential kinetics of immune responses elicited by Covid-19 vaccines","volume":"385","author":"Collier","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2022.07.023_b0155","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1473-3099(21)00681-2","article-title":"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials","volume":"22","author":"Zeng","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2022.07.023_b0160","doi-asserted-by":"crossref","first-page":"e002019","DOI":"10.1136\/rmdopen-2021-002019","article-title":"Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series","volume":"7","author":"Assawasaksakul","year":"2021","journal-title":"RMD Open"},{"issue":"11","key":"10.1016\/j.vaccine.2022.07.023_b0165","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/s41591-021-01527-y","article-title":"Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis","volume":"27","author":"Choi","year":"2021","journal-title":"Nat Med"},{"issue":"10318","key":"10.1016\/j.vaccine.2022.07.023_b0170","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.vaccine.2022.07.023_b0175","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.vaccine.2022.07.023_b0180","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.3201\/eid2712.211772","article-title":"Limited and short-lasting virus neutralizing titers induced by inactivated SARS-CoV-2 vaccine","volume":"27","author":"Hunsawong","year":"2021","journal-title":"Emerg Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2022.07.023_b0185","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/s41591-021-01432-4","article-title":"A correlate of protection for SARS-CoV-2 vaccines is urgently needed","volume":"27","author":"Krammer","year":"2021","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.vaccine.2022.07.023_b0190","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat Med"},{"issue":"6576","key":"10.1016\/j.vaccine.2022.07.023_b0195","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2022.07.023_b0200","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejca.2021.12.011","article-title":"Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: should humoral responses be monitored? A position article","volume":"162","author":"Barri\u00e8re","year":"2022","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.vaccine.2022.07.023_b0205","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00281-21","article-title":"COVID-19 severity is associated with differential antibody Fc-mediated innate immune functions","volume":"12","author":"Adeniji","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2022.07.023_b0210","article-title":"Anti-SARS-CoV-2 hyperimmune globulin demonstrates potent neutralization and antibody-dependent cellular cytotoxicity and phagocytosis through N and S proteins","author":"Diez","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.07.023_b0215","doi-asserted-by":"crossref","first-page":"618685","DOI":"10.3389\/fimmu.2020.618685","article-title":"Distinct features and functions of systemic and mucosal humoral immunity among SARS-CoV-2 convalescent individuals","volume":"11","author":"Butler","year":"2020","journal-title":"Front Immunol"},{"issue":"10296","key":"10.1016\/j.vaccine.2022.07.023_b0220","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(21)01543-9","article-title":"CoronaVac: more data for regulators and policy makers","volume":"398","author":"Ramasamy","year":"2021","journal-title":"Lancet"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22009112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22009112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:16:44Z","timestamp":1759403804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22009112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":44,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0264410X22009112"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.07.023","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.07.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}